LIC MF Healthcare Fund
- NAV as on 9 Nov 2026
- ₹34.65+2.77%1 day
- Return since launch
- 17.1%
- 52-week range
- ₹26.94 — ₹34.73
- AUM
- ₹99.36 Cr
LIC MF Healthcare Fund is a Sectoral-Pharma equity fund from LIC Mutual Fund with ₹99.36 Cr under management, launched in 2019. Over three years it has returned 15.4% a year, against 21.2% for its category. The expense ratio is 2.68% and the SEBI riskometer reading is Very High.
Performance
LIC MF Healthcare Fund NAV and returns
Growth of the fund against its category average over the period you pick.
Over 1Y this fund returned +16.0% against +19.4% for its category.
Performance
Returns
How the fund has done against its category and its benchmark.
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1Y | 26.2% | +5.6 pts | 20.6% | 29.1% |
| 2Y | 15.8% | −3.0 pts | 18.8% | 17.6% |
| 3Y | 15.4% | −5.8 pts | 21.2% | 16.0% |
| 5Y | 17.5% | +2.2 pts | 15.3% | 18.5% |
| 7Y | 16.3% | −2.5 pts | 18.8% | 18.0% |
| Period | Fund | vs category | Category | Benchmark |
|---|---|---|---|---|
| 1M | 7.3% | −0.8 pts | 8.1% | 8.5% |
| 3M | 2.2% | −1.4 pts | 3.6% | 3.7% |
| 6M | 11.2% | −2.5 pts | 13.8% | 13.6% |
| 1Y | 16.0% | −4.6 pts | 20.6% | 19.4% |
| 2Y | 8.1% | −2.6 pts | 10.6% | 9.5% |
| 3Y | 20.3% | −0.9 pts | 21.2% | 20.0% |
| 5Y | 12.8% | −2.5 pts | 15.3% | 14.6% |
| 7Y | 19.0% | −3.3 pts | 22.3% | 21.2% |
Since launch (8 Feb 2019): 17.1%
Calendar-year returns
Category averageShow as a table
| Period | Fund | vs category | Category |
|---|---|---|---|
| 2025 | -4.4% | −2.4 pts | -2.0% |
| 2024 | 41.7% | +0.8 pts | 40.9% |
| 2023 | 27.8% | −8.4 pts | 36.2% |
| 2022 | -12.7% | −4.4 pts | -8.3% |
| 2021 | 14.5% | −7.2 pts | 21.7% |
| 2020 | 58.2% | −10.6 pts | 68.8% |
Returns over one year are annualised. Shorter periods are absolute.
Costs & terms
Costs and terms
What the fund charges each year, and the rules around putting money in and taking it out.
Costs
2.72%
Expense ratio as on 7 Nov 2026
Charged yearly and already deducted from the NAV.
- Base expense
- 2.10%
- Brokerage
- 0.09%
- Transaction charges
- 0.01%
- Statutory levies
- 0.52%
- Exit load
- Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days.
- Lock-in
- None
Terms
- Min SIP
- ₹3,000
- Min lumpsum
- ₹5,000
- Plan
- GROWTH
- Fund type
- OPEN-ENDED
- Benchmark
- BSE Healthcare TRI
- Short-term capital gains
- Returns taxed at 20% if you redeem before 1 year
- Long-term capital gains
- After 1 year, returns above ₹1.25 lakh in a financial year are taxed at 12.5%
Risk
Risk
What the riskometer means for this fund, and how its ratios sit against the category.
Your principal is treated as being at very high risk — typically small cap, sectoral and thematic equity schemes.
| Ratio | Fund | Category avg | Read as |
|---|---|---|---|
| Alpha | -1.21 | 1.49 | Return earned above what the benchmark alone would have given. Higher is better. |
| Beta | 0.95 | 0.94 | How hard the fund moves when the market moves. Under 1 is steadier than the market. |
| Sharpe | 0.92 | 1.10 | Return earned for each unit of total risk taken. Higher is better. |
| Sortino | 1.37 | 1.81 | Return earned for each unit of downside risk. Higher is better. |
| Std. deviation | 16.11 | 15.62 | How widely monthly returns have varied around their own average. Lower is steadier. |
| Average of 5 category peers | |||
Portfolio
LIC MF Healthcare Fund portfolio
Portfolio as of 30 Sep 2026
Asset allocation
- Equity97.5%
- Other2.5%
Market cap split
- Large31.2%
- Mid32.8%
- Small36.0%
- P/E
- 51.93
- P/B
- 6.09
Top holdings
| Holding | Sector | Weight | Value | 3M chg | 6M chg | 1Y chg |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 9.59% | ₹9.53 Cr | +10.55% | +11.77% | +10.08% |
| Divi's Laboratories Ltd. | Healthcare | 9.07% | ₹9.01 Cr | +7.17% | +4.68% | +4.11% |
| Neuland Laboratories Ltd. | Healthcare | 6.14% | ₹6.10 Cr | +5.74% | +3.97% | +4.14% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 6.04% | ₹6.00 Cr | +6.55% | +7.08% | +5.55% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5.75% | ₹5.72 Cr | +6.77% | +6.84% | +5.85% |
| Aurobindo Pharma Ltd. | Healthcare | 5.23% | ₹5.19 Cr | +5.30% | +5.21% | +3.98% |
| Navin Fluorine International Ltd. | Chemicals | 4.98% | ₹4.95 Cr | +5.58% | +3.24% | +2.60% |
| Zydus Lifesciences Ltd. | Healthcare | 4.97% | ₹4.94 Cr | +5.11% | — | — |
| Aster DM Quality Care Ltd. | Healthcare | 4.61% | ₹4.58 Cr | +3.18% | — | — |
| Fortis Healthcare Ltd. | Healthcare | 3.77% | ₹3.74 Cr | +4.45% | +4.37% | +4.79% |
| Metropolis Healthcare Ltd. | Healthcare | 3.35% | ₹3.33 Cr | +2.76% | +2.62% | +2.73% |
| Gland Pharma Ltd. | Healthcare | 3.20% | ₹3.18 Cr | +3.79% | +3.04% | +3.12% |
| Mankind Pharma Ltd. | Healthcare | 3.11% | ₹3.09 Cr | +2.36% | +2.20% | +2.45% |
| Nephrocare Health Services Ltd. | Healthcare | 3.05% | ₹3.03 Cr | — | — | — |
| Max Healthcare Institute Ltd. | Healthcare | 2.99% | ₹2.98 Cr | +2.05% | +2.06% | +2.19% |
| Cohance Lifesciences Ltd. | Healthcare | 2.95% | ₹2.93 Cr | — | — | — |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 2.61% | ₹2.59 Cr | +2.86% | +3.27% | +2.75% |
| Global Health Ltd. | Healthcare | 2.59% | ₹2.58 Cr | +3.16% | +1.84% | +2.31% |
| Others | Others | 2.47% | ₹2.45 Cr | -0.86% | -0.30% | -1.19% |
| Dr. Agarwal's Health Care Ltd. | Healthcare | 2.46% | ₹2.44 Cr | +2.05% | +2.05% | +2.96% |
| Biocon Ltd. | Healthcare | 2.37% | ₹2.35 Cr | +2.87% | — | — |
| Ipca Laboratories Ltd. | Healthcare | 2.33% | ₹2.31 Cr | +3.05% | +3.40% | +2.88% |
| Onesource Specialty Pharma Ltd. | Healthcare | 2.30% | ₹2.28 Cr | +2.67% | +4.17% | +2.61% |
| Piramal Pharma Ltd. | Healthcare | 1.43% | ₹1.43 Cr | — | +3.94% | +4.45% |
| Syngene International Ltd. | Healthcare | 1.38% | ₹1.37 Cr | — | — | +2.07% |
| Artemis Medicare Services Ltd. | Healthcare | 1.26% | ₹1.25 Cr | +2.68% | +2.45% | +2.99% |
Sectors
Instruments
Recent changes
| Holding | From | To | Weight |
|---|---|---|---|
| Nephrocare Health Services Ltd. | 0.00% | 3.05% | +3.05% |
| Artemis Medicare Services Ltd. | 2.88% | 1.26% | -1.62% |
| Piramal Pharma Ltd. | 0.00% | 1.43% | +1.43% |
| Ipca Laboratories Ltd. | 3.18% | 2.33% | -0.85% |
| Gland Pharma Ltd. | 3.93% | 3.20% | -0.73% |
| Navin Fluorine International Ltd. | 5.65% | 4.98% | -0.67% |
| Global Health Ltd. | 3.19% | 2.59% | -0.60% |
| Sun Pharmaceutical Industries Ltd. | 10.09% | 9.59% | -0.50% |
| Apollo Hospitals Enterprise Ltd. | 6.23% | 5.75% | -0.48% |
| Max Healthcare Institute Ltd. | 2.55% | 2.99% | +0.44% |
| Torrent Pharmaceuticals Ltd. | 6.45% | 6.04% | -0.41% |
| Syngene International Ltd. | 0.97% | 1.38% | +0.41% |
| Glenmark Pharmaceuticals Ltd. | 2.88% | 2.61% | -0.27% |
| Neuland Laboratories Ltd. | 6.38% | 6.14% | -0.24% |
| Divi's Laboratories Ltd. | 9.29% | 9.07% | -0.22% |
| Mankind Pharma Ltd. | 2.89% | 3.11% | +0.22% |
| Aster DM Quality Care Ltd. | 4.82% | 4.61% | -0.21% |
| Zydus Lifesciences Ltd. | 4.79% | 4.97% | +0.18% |
| Metropolis Healthcare Ltd. | 3.17% | 3.35% | +0.18% |
| Biocon Ltd. | 2.54% | 2.37% | -0.17% |
| Onesource Specialty Pharma Ltd. | 2.21% | 2.30% | +0.09% |
| Dr. Agarwal's Health Care Ltd. | 2.54% | 2.46% | -0.08% |
| Aurobindo Pharma Ltd. | 5.17% | 5.23% | +0.06% |
| Cohance Lifesciences Ltd. | 2.92% | 2.95% | +0.03% |
| Fortis Healthcare Ltd. | 3.78% | 3.77% | -0.01% |
| Others | -0.10% | -0.10% | 0.00% |
Compare
Similar funds
The rest of the category, so this fund’s numbers have something to sit against.
| Fund | AUM | Expense | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Category average | ₹2,892 Cr | 1.89% | 36.5% | 20.8% | 21.6% |
 SBI Healthcare Opportunities Fund | ₹5,870 Cr | 1.98% | 35.0% | 19.9% | 22.6% |
 HDFC Pharma And Healthcare Fund | ₹3,501 Cr | 2.11% | 39.6% | 25.8% | — |
 Mirae Asset Healthcare Fund | ₹3,494 Cr | 2.01% | 37.3% | 20.2% | 21.1% |
 UTI Healthcare Fund | ₹1,430 Cr | 2.21% | 30.6% | 18.4% | 21.1% |
 ICICI Prudential Nifty Pharma Index Fund | ₹163 Cr | 1.13% | 39.9% | 19.9% | — |
About
About this fund
The scheme’s own words, its benchmark and the people running it.
Investment objective
The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.
Fund managers
- Sudhanshu AsthanaMr. Asthana is a M.A (Economics) from Mumbai University and PGDM (Investment Management) from NMIMS.Prior to joining LIC MF, he has worked with UTI Mutual Fund, Tamohara Investment Managers, Axis Mutual Fund, Barclays Wealth Management, SBI Mutaul Fund, Quantum Mutual Fund and BRICS Securities Ltd.
Tools
Return calculator
What ₹10,000 a month in this fund would have grown to over each period, based on its past returns.
| Over the past | Total investment | Would’ve become | Growth | Returns |
|---|---|---|---|---|
| 6 months11.23% absolute | ₹60,000 | ₹66,738 | 11.23% | |
| 1 year16.00% annualised | ₹1,20,000 | ₹1,30,926 | 9.10% | |
| 3 years20.26% annualised | ₹3,60,000 | ₹4,98,158 | 38.38% | |
| 5 years12.81% annualised | ₹6,00,000 | ₹8,43,570 | 40.59% |
Returns for 1 year and longer are annualised (CAGR); 6-month figures are absolute. Past returns are not a forecast.
How this is calculated
Each monthly instalment grows at the fund’s annualised return ÷ 12 per month until the end of the period, the same formula as our SIP calculator.
The amount compounds once a year at the fund’s CAGR for that period, the same formula as our lumpsum calculator.
Questions
Frequently asked questions
The things people ask about this scheme.